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Differential effects of simvastatin on mesangial cells
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Differential effects of simvastatin on mesangial cells.
Background. Statins are increasingly recognized as media-
tors of direct cellular effects independent of their lipid lowering
capacity. Therefore, the time and concentration dependence of
various statin-mediated cellular alterations was compared in
renal mesangial cells.
Methods. The effects of statins on cell proliferation, gene
expression, cytoskeletal alterations, apoptosis, and cytotoxic-
ity were analyzed in cultured mesangial cells using standard
techniques.
Results. Simvastatin and lovastatin decreased prolifera-
tion and cell number of rat mesangial cells concentration-
dependently. Concurrently, the expression of the fibrogenic pro-
tein connective tissue growth factor (CTGF) was impaired and
actin stress fibers, which are typical of mesangial cells in cul-
ture, became disassembled by simvastatin. A decrease of the
posttranslational modification of RhoA by geranylgeranyl moi-
eties was detected, supporting a role for RhoA as mediator of
statin effects. Induction of apoptosis, determined by activation
of caspase-3 and DNA fragmentation, and necrosis only oc-
curred at later time points, when the morphology of the cells
was strongly altered and the cells detached from the surface due
to changes in the actin cytoskeleton. Basically, the same results
were obtained with a human mesangial cell line. Furthermore,
statin effects were mimicked by inhibition of the geranylger-
anyltransferase.
Conclusion. Most of the cellular effects of the lipophilic
statins occurred within the same time and concentration range,
suggesting a common molecular mechanism. Only apoptosis
and necrosis were observed at later time points or with higher
concentrations of simvastatin and thus seem to be secondary
to the changes in gene expression and alterations of the actin
cytoskeleton.
3-hydroxy-e-methylglutaryl coenzyme A (HMG CoA)
reductase inhibitors (statins) have been shown to ame-
liorate glomerular disease in animal models as well as in
patients [1–4]. These beneficial effects are mediated at
least in part by direct cellular effects of statins. Statins
interfere with the isoprenylation of signaling molecules
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(e.g., proteins of the Rho and Ras families) and thus
affect multiple cellular functions [5, 6]. In vitro studies
showed inhibition of mesangial cell proliferation [7, 8],
and induction of apoptosis [9], inhibition of transforming
growth factor-b (TGF-b) expression and matrix accumu-
lation [10, 11], inhibition of mesangial cell production of
monocyte chemoattractant protein-1 (MCP-1) [12], and
modulation of interleukin-6 (IL-6) and intercellular ad-
hesion molecule-1 (ICAM-1) expression [13]. All these
effects were due to inhibition of HMG CoA reductase,
and shown to be dependent on farnesylation and/or ger-
anylgeranylation of signaling molecules. The cited stud-
ies were performed with different types of mesangial
cells and with different statins. Most experiments were
performed with cell permeable statins such as lovas-
tatin, simvastatin, or cerivastatin, whereas other groups
used pravastatin, which barely penetrates through cellu-
lar membranes [14]. Furthermore, the time of treatment
varied from several hours to several days. Therefore, it is
difficult to compare the present literature and to answer
the question, whether the pleiotropic effects of statins
all occurred at the same time and within the same con-
centration range. Because different concentrations were
used, it is difficult to decide whether all effects must be
considered pharmacologic or whether some of them only
occurred at much higher concentrations and are to be
taken for toxic effects.
Rho proteins as targets of statin action are discussed in
most studies dealing with the effects of statins on mesan-
gial cells. One of the major functions of these proteins
is to organize the actin cytoskeleton, with Rho being in-
volved in the generation and maintenance of stress fibers,
Rac in the build up of lamellipodia and Cdc42 in the de-
velopment of actin spikes and filopodia [15]. Even under
physiologic conditions, mesangial cells are under tension
and exposed to high static pressure, which may vary un-
der pathophysiologic conditions. It thus seems to be of
interest to consider cytoskeletal effects of statins in this
type of cell.
Therefore, a study was designed to investigate in one
type of mesangial cells the effects of simvastatin on cell
proliferation, apoptosis, gene expression, and alterations
of the actin cytoskeleton. As an example of a statin-
sensitive gene we chose connective tissue growth factor,
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the expression of which has been shown to be critically de-
pendent on the activity of Rho proteins [16–18]. Simvas-
tatin and lovastatin were used as cell-permeable statins,
which are widely used therapeutically.
METHODS
Materials
Y27632 was kindly provided by Yoshitomi Pharmaceu-
tical Industries (Osaka, Japan). Simvastatin and lovas-
tatin were kindly provided by MSD, Sharp and Dohme
(Mu¨nchen, Germany). The statins were dissolved in
ethanol and activated as described by Jakobisiak et al [19].
The inhibitor of the geranylgeranyl transferase, L841, was
kindly provided by R.B. Lobell (Merck Research Lab-
oratories, West Point, NY, USA) [20]. Lysophosphatidic
acid was from Sigma (Mu¨nchen, Germany); recombinant
human (TGF-b) was obtained from Tebu (Frankfurt,
Germany).
Cell culture
Mesangial cells, obtained from Sprague-Dawley rats,
were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 2 mmol/L L-glutamine,
5 lg/mL insulin, 4.5 g/L glucose, 100 U/mL penicillin.
and 100 lg/mL streptomycin containing 10% (vol/vol) fe-
tal calf serum (FCS). Mesangial cells were used between
passages 12 and 25. For the experiments, renal mesangial
cells (0.5 × 106 cells/10 mL) were plated in 10 cm di-
ameter Petri dishes in medium with 10% (vol/vol) FCS.
A human mesangial cell line was kindly provided by B.
Banas (Mu¨nchen, Germany) and cultured as described
previously [21].
Analysis of mesangial cell proliferation
Mesangial cells (4000 cells/well) were seeded in qua-
druplicates in medium containing 10% FCS in 96-well
microtiter plates. The next day, simvastatin was added
as indicated. After 20 and 42 hours, [3H]-thymidine
(2.5 lCi/mL) was added for 4 hours. Thereafter, the cells
were frozen overnight and harvested onto glass fiber fil-
ters with an automatic cell harvester. Radioactivity incor-
porated into DNA was counted in a Beckmann LS6000IC
beta counter.
As a measure of cell numbers, the cells were treated
with alamar blue (Laboserv, Giessen, Germany) for the
last 3 hours. The fluorescence of the reduced form of the
dye was monitored at 530 nm excitation wavelength and
590 nm emission wavelength using a plate fluorimeter
(Spectra Fluor; Tecan, Vienna, Austria).
Analysis of mesangial cell cytotoxicity
Mesangial cells were treated as described above. Af-
ter 48 hours, cellular supernatants were analyzed for re-
lease of adenylate kinase using the ToxiLight Assay from
BioWhittaker (Verviers, Belgium).
Quantification of DNA fragmentation
DNA fragmentation was measured with the dipheny-
lamine assay as reported [22, 23]. Following incubations,
cells (5 × 105 cells/assay) were scraped off the cul-
ture plates, resuspended in 250 lL Tris/ethylenediamine-
tetraacetic acid (EDTA) buffer (10 mmol/L Tris/HCl,
pH 8.0, and 1 mmol/L EDTA) and lysed for at least
30 minutes at 4◦C by adding 250 lL cold lysis buffer
[20 mmol/L EDTA, 0.5% Triton X-100 (vol/vol), and 5
mmol/L Tris/HCl, pH 8.0]. Intact chromatin (pellet) was
then separated from DNA fragments (supernatant) by
centrifugation for 10 minutes at 13,000g, 4◦C. Pellets were
resuspended in 500 lL Tris/EDTA buffer, and samples
(pellets and supernatants) were precipitated overnight
at 4◦C by adding 500 lL of 10% trichloroacetic acid
(TCA). DNA was pelleted by centrifugation (4000g)
for 10 minutes and the supernatant was discarded. The
DNA was hydrolyzed by boiling for 15 minutes in 300
lL 5% TCA. 50 lL of the DNA containing solution was
mixed with 100 lL diphenylamine solution (88 mmol/L
diphenylamine, 98% vol/vol glacial acetic acid, 1.5%
vol/vol sulfuric acid, and 0.5% vol/vol of 1.6% acetalde-
hyde). Absorption of duplicate samples was measured at
570 nm in a plate reader. The percentage of fragmented
DNA was calculated as the ratio of the DNA in the su-
pernatant to total DNA content.
Determination of caspase-3 activity
After incubation as indicated, mesangial cells
were harvested and resuspended in lysis buffer [100
mmol/L Hepes, pH 7.5, 10% sucrose, 0.1% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate
(CHAPS), and 1 mmol/L EDTA]. Following sonification
(Branson sonifier, 15 seconds, 40% output) samples
were incubated for 30 minutes on ice. After centrifu-
gation (10,000 × g) for 10 minutes at 4◦C protein was
determined with the Bio-Rad Protein Assay (Bio-Rad,
Mu¨nchen, Germany). Cell lysates (30 lg protein) were
incubated in lysis buffer with 10 mmol/L dithiotreitol
(DTT) at 30◦C with 12 lmol/L of the caspase-3 substrate
N-Acetyl-Asp-Glu-His-Asp-7-amido-4-methylcoumarin
trifluoroacetate (Ac-DEVD-AMC) (Biomol, Hamburg,
Germany). Substrate cleavage and accumulation of
AMC were followed fluorometrically with excitation at
360 nm and emission at 460 nm during an incubation
period of 120 minutes. Enzyme activity was calculated as
fluorescence units per mg protein per hour. To determine
cleavage of procaspase-3, cell lysates were analyzed by
Western blotting using an anticaspase-3 antibody from
BD Transduction Laboratories (Lexington, KY, USA).
Northern blot analysis
To obtain total RNA the cells were scraped with a rub-
ber policeman into chilled 50 mL polypropylene tubes
and spun down (225g, 4◦C). The pellet was lysed by
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adding 300 lL guanidinium isothiocyanate-containing
lysis solution. Total RNA was extracted by standard pro-
cedures. RNA yield usually was 30 to 40 lg/10 cm diam-
eter Petri dish.
Separation of total RNA (10 lg/lane) was achieved
by the use of 1.2% agarose gels containing 1.9% (vol/
vol) formaldehyde with 1 × 3-[N-morpholino]propane-
sulfonic acid) (MOPS) as gel/running buffer. Separated
RNA was transferred to nylon membranes by capillary
blotting and fixed by baking at 80◦C for 2 hours.
Hybridization was performed with cDNA probes la-
beled with [32P] deoxycytidimine triphosphate (dCTP)
using the Nonaprimer Kit (Qiagen, Hilden, Germany).
A cDNA specific for connective tissue growth factor was
kindly provided by N. Abdel-Wahab (London, UK) [24].
DNA/RNA hybrids were detected by autoradiography
using Kodak X-Omat AR film and quantified by densito-
metric scanning. As a control for equal loading of the gels,
the 18S rRNA was stained with methylene blue (0.04%
in 500 mmol/L sodium acetate, pH 5.2) and directly quan-
tified by densitometry. All values were corrected for
differences in RNA loading by calculating the ratio of
connective tissue growth factor (CTGF) to 18S or 28S
rRNA expression.
Western blot analysis
CTGF was detected in cellular homogenates by West-
ern blot analysis. In brief, cells were rinsed twice with ice-
cold phosphate-buffered saline (PBS) and then scraped
in 90 lL lysis buffer [50 mmol/L HEPES, pH 7.4,
150 mmol/L NaCl, 1 mmol/L EDTA, 1% (vol/vol) Tri-
ton X-100, 10% (wt/vol) glycerol, 1 mmol/L phenyl-
methylsulfonyl fluoride (PMSF), 10 lg/mL aprotinin,
10 lg/mL leupeptin, 10 mmol/L sodium orthovana-
date, and 25 mmol/L sodium fluoride). Lysates were
incubated for 30 minutes on ice and then centrifuged
at 15,000g for 15 minutes to collect supernatants. Thirty
micrograms of total protein were separated by 12%
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) and electroblotted onto fluorotrans
transfer membrane (Pall, Biosupport Division, Dreieich,
Germany). The following primary antibodies were used:
polyclonal anticonnective tissue growth factor, antitubu-
lin, and anti-b actin (Santa Cruz Biotechnology, Heidel-
berg, Germany). The peroxidase-conjugated antirabbit
secondary antibody was obtained from Amersham Bio-
sciences (Freiburg, Germany), the antigoat secondary an-
tibody was from Santa Cruz Biotechnology (Heidelberg,
Germany). Protein-antibody complexes were visualized
by the enhanced chemiluminescence (ECL) detection
system (Amersham Biosciences, Freiburg, Germany).
Staining of actin filaments
Cells were cultured and growth arrested on glass 8-
well multitest slides placed in a Petri dish. Further treat-
ment with statins was carried out in wet chambers. At the
end of the incubation period, cells were fixed with 3%
paraformaldehyde in PBS for 10 minutes and then perme-
abilized with 0.2% Triton X-100 in PBS for 7 minutes at
room temperature. To examine DNA fragmentation cells
were incubated with Hoechst 33258 (8 lg/mL) for 5 min-
utes. Rhodamine-phalloidin (Molecular Probes, Eugene,
OR, USA) was used for the staining of the actin skeleton
at a dilution of 1:80 in PBS for 20 minutes. Staining was
analyzed by fluorescence microscopy and photographs
were taken using the software Meta View (Leica, Ben-
sheim, Germany).
Separation of isoprenylated and nonisoprenylated RhoA
Isoprenylated RhoA was determined essentially as de-
scribed by Chappell et al [25]. After treatment with or
without simvastatin, whole cell lysates were prepared
in lysis buffer (1 mmol/L Na3PO4, 50 mmol/L Hepes,
5 mmol/L MgCl2, 150 mmol/L NaCl, 0.05% SDS, and 1%
Triton X-100). Cells were sonicated two times for 10 sec-
onds, 50% output (Branson sonifier) and debris removed
by centrifugation. Lysate containing about 450 lg protein
was mixed with an equal volume of 4% Triton X-114 and
warmed to 37◦C for 3 minutes. Separation of a Triton-rich
lower phase containing the isoprenylated form of RhoA,
and an upper buffer phase containing the nongeranyl-
geranylated form occurred at room temperature. Before
analysis by SDS-PAGE, the protein of the lower phase
was precipitated by ethanol and the pellet resuspended in
20 mmol/L Tris/HCl, pH 8.0, and 1 mmol/L EDTA. RhoA
was detected by Western blot analysis, using an antibody
from Santa Cruz Biotechnology (Heidelberg, Germany).
Due to the different treatment of both phases, different
gels and exposure time necessary to detect RhoA, it was
not possible to quantitate the percentage of geranylger-
anylated RhoA by this method.
Statistics
The means of different experimental groups were ana-
lyzed by the two-sided Student t test. A value of P < 0.05
was considered significant.
RESULTS
Inhibition of mesangial cell proliferation by simvastatin
Mesangial cells were seeded in medium containing
10% serum. One day later the cells were treated with
different concentrations of simvastatin or lovastatin for
24 hours. Proliferation was assessed by [3H]-thymidine in-
corporation. At a concentration of 10 lmol/L, both statins
reduced the incorporation by about 40% (Fig. 1A). In
accordance with this result, the cell number was reduced
after 48 hours of incubation with simvastatin to a simi-
lar extent (Fig. 1B). Statins inhibit farnesylation and ger-
anylgeranylation of proteins. Treatment of the cells with
a specific inhibitor of geranylgeranyl transferase, L841,
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Fig. 1. Interference of statins with rat mesan-
gial cell proliferation. (A) Mesangial cells
were cultured in medium containing 10%
fetal calf serum (FCS) in the presence of dif-
ferent concentrations of simvastatin or lo-
vastatin for 24 hours. The cells were incu-
bated with [3H]-thymidine for the last 4 hours.
Data () are mean ± SEM of three indepen-
dent experiments performed in quadruplicate.
∗P < 0.05, ∗∗P < 0.02 compared to cells treated
with 1 lmol/L simvastatin (•) N = 2, mean ±
half range of the mean. (B) Mesangial cells
were cultured as in (A) but incubated for 48
hours. As a measure of cell number, the flu-
orescence of alamar blue was determined as
described in the Methods section. Data are
mean ± SEM of four experiments performed
in quadruplicate. ∗P < 0.05, ∗∗P < 0.01 com-
pared to cells treated with 1 lmol/L simvas-
tatin. (C) Mesangial cells were cultured as in
(A) and treated with the geranylgeranyl trans-
ferase inhibitor L841 for 24 hours. Data are
mean ± SEM of three independent experi-
ments. ∗P < 0.05, ∗∗P < 0.01 compared to cells
treated with 0.1 nmol/L L841. (D) Mesangial
cells were cultured as in (B) and treated with
the geranylgeranyl transferase inhibitor L841
for 48 hours. Data are mean of one experiment
performed in quadruplicate.
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Fig. 2. Sensitivity of connective tissue growth
factor (CTGF) expression to statin treatment.
(A) Mesangial cells, cultured in 10% fetal
calf serum (FCS), were treated with increas-
ing concentrations of simvastatin for 24 hours.
RNA was extracted and CTGF mRNA de-
tected by Northern blot analysis. (B) To com-
pare different experiments, the expression
of CTGF mRNA (•) in untreated cells was
set to 100%. Data are means ± SD of four
experiments. ∗∗P < 0.02 compared to cells
treated with 1 lmol/L simvastatin. Data on
connective tissue growth factor protein (),
48 hours, are mean ± SD of three experi-
ments. ∗∗P < 0.02 compared to cells treated
with 1 lmol/L simvastatin. (C) Serum-starved
mesangial cells were preincubated with sim-
vastatin for 24 hours and with Y27632 (Y),
10 lmol/L, for 30 minutes. Thereafter, the cells
were stimulated with lysophosphatidic acid
(LPA) (10 lmol/L) for 2 hours. (D) Cells were
treated as in (C), but stimulated with trans-
forming growth factor-b (TGF-b , 5 ng/mL)
for 6 hours. CTGF protein was detected by
Western blot analysis.
markedly inhibited mesangial cell proliferation and de-
crease mesangial cell numbers, pointing to a role for Rho
proteins in the regulation of cell proliferation (Fig. 1C
and D).
Inhibition of connective tissue growth factor
expression by simvastatin
Basal CTGF mRNA and protein expression was ob-
served in proliferating mesangial cells (Fig. 2A and D).
Treatment of the cells for 24 hours with simvastatin re-
duced the basal expression in a concentration-dependent
manner (Fig. 2B). Significant inhibition was observed at
10 and 30 lmol/L of simvastatin. Similar results were
obtained with growth-arrested cells which were stimu-
lated with lysophosphatidic acid (LPA), a known inducer
of CTGF (Fig. 2C). The inhibition by 10 lmol/L sim-
vastatin was comparable to the reduction by the com-
pound Y27632, a specific inhibitor of RhoA signaling via
RhoA-associated kinase. Induction of CTGF by TGF-b
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Fig. 3. Alterations of the organization of the actin cytoskeleton.
Mesangial cells were cultured on glass cover slips for 24 hours in medium
containing 10% fetal calf serum (FCS) in the presence of increasing
concentrations of simvastatin as indicated. The actin cytoskeleton was
visualized by rhodamine phalloidin staining.
determined after 6 or 24 hours, however, was independent
of the basal levels and was not affected by simvastatin
in these cells. Ten micromol/L simvastatin reduced basal
CTGF protein levels to 44.3+/−13.4% of control com-
pared to no reduction of the stimulated CTGF expres-
sion [99.6+/−8.1% of TGF-b stimulation in the absence
of simvastatin, 24 hours (N = 3, P < 0.005), compared to
the effect in nonstimulated cells].
Modulation of the actin cytoskeleton
Mesangial cells were incubated with different concen-
trations of simvastatin overnight and the actin cytoskele-
ton was visualized by staining with rhodamine phalloidin.
Mesangial cells showed a high degree of actin stress fibers
spanning the cytosol of the cells (Fig. 3). Upon treatment
with simvastatin, the dense net of fibers loosened and
gradually disappeared. At low concentrations of simvas-
tatin (3 lmol/L) the cell spanning stress fibers began to
disassemble. Higher concentrations led to a complete dis-
integration of the cytosolic fibers, with the cortical actin
fibers still intact. At 30 lmol/L the cells had a spindle-like
appearance with some F-actin condensed around the nu-
cleus. Because of the disintegration of the cortical actin
fibers, the shape of the cells was barely visible when F-
actin was stained.
Modification of RhoA
RhoA is one of the major regulators of actin stress fiber
formation. In order to become activated, RhoA needs
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Fig. 4. Modulation of the isoprenylation of RhoA. (A) Mesangial cells
in 10% fetal calf serum (FCS) were treated with simvastatin (0 to 30
lmol/L) for 24 hours. The expression of RhoA was detected by Western
blot analysis in whole cell homogenates. (B) Equal amounts of cellu-
lar protein were separated into geranylgeranylated (RhoA + GG) and
nongeranylgeranylated RhoA (RhoA – GG) by the Triton X-114 ex-
traction method. RhoA was detected by Western blot analysis. The
blot is representative of three independent experiments with similar
results.
to be isoprenylated with geranylgeranyl residues. There-
fore, the effect of simvastatin on RhoA isoprenylation
was investigated. Simvastatin induced a concentration-
dependent increase in total RhoA protein, as detected
by Western blotting of whole cell lysates (Fig. 4A). The
geranylgeranylated (RhoA + GG) and the nongeranyl-
geranylated form of RhoA (RhoA – GG) were separated
by Triton X-114 extraction. In control cells, only geranyl-
geranylated RhoA was detectable (Fig. 4B). Upon treat-
ment with simvastatin, the proportion of the nongeranyl-
geranylated form increased while the geranylgeranylated
form decreased. Nongeranylgeranylated RhoA was de-
tectable at 3 lmol/L simvastatin.
Induction of apoptosis in mesangial cells
To detect apoptosis, an early and a late marker of
apoptosis were determined, namely caspase-3 activity
and DNA fragmentation. Proliferating mesangial cells
showed very little caspase activity which was close to the
assay baseline values. In some cell preparations, a small
increase in caspase activity was observed after incuba-
tion with 10 lmol/L simvastatin for 24 hours (Fig. 5A).
Only high concentrations of simvastatin (30 lmol/L) ac-
tivated caspase-3 significantly after 24 hours and more
prominently after 48 hours. The high variability of the
response after 24 hours was due in part to the low
baseline values, which served as reference. Furthermore,
24 hours seemed to be a transition time where in some ex-
periments caspase-3 was already fully activated, whereas
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Fig. 5. Induction of apoptosis and cytotoxic-
ity by high concentrations of simvastatin. (A)
Mesangial cells were cultured in medium con-
taining 10% fetal calf serum (FCS) with differ-
ent concentrations of simvastatin for 24 hours
() and 48 hours ( ). Caspase activity of con-
trol cells was set to 1 in each experiment. Data
are means ± SD of 3 to 11 experiments for the
different conditions. ∗P < 0.05, ∗∗P < 0.005
compared to cells treated with 3 lmol/L sim-
vastatin. (B) Mesangial cells were cultured in
medium containing 10% FCS () or growth
arrested in 0.5% serum () for 24 hours and
then further incubated with simvastatin for
another 24 hours. Caspase activity (fluores-
cence units per lg protein per hour, means ±
half range) of two experiments performed in-
dependently is depicted. (C) Mesangial cells
were cultured in medium containing 10% FCS
with 30 lmol/L simvastatin () in the pres-
ence of increasing concentrations of geranyl-
geranylpyrophosphate (GGPP) ( ) or farne-
sylpyrophosphate (FPP) ().The caspase ac-
tivity of the cells treated with 30 lmol/L sim-
vastatin was set to 100. Data are representa-
tive of two experiments with similar results.
(D) Mesangial cells were growth-arrested or
cultured in 10% serum. After treatment with
simvastatin for 24 hours () or 48 hours (),
the percentage of apoptotic cells was deter-
mined by the diphenylamine assay. Data are
means ± half range of two independent ex-
periments for each condition. (E) Proliferat-
ing mesangial cells were treated with simvas-
tatin () or lovastatin ( ) for 48 hours. Cyto-
toxicity was determined by adenylate kinase
release from the cells. Data are means +/−
SEM of three experiments. ∗P < 0.05 com-
pared to cells treated with 1 lmol/L statin.
(F) Proliferating mesangial cells were treated
with L841 for 24 hours to determine caspase
activity (fluorescence units per lg protein per
hour) and for 48 hours to determine cyto-
toxicity by adenylate kinase release. Data are
means ± SD of triplicate cell cultures. ∗∗P <
0.001.
in other experiments, activation just got started. Af-
ter 48 hours, activation of caspase-3 was evident in all
experiments, when cells were treated with 30 lmol/L
simvastatin.
If the cells were growth-arrested in medium with 0.5%
FCS for 24 hours prior to the incubation with simvas-
tatin, a treatment often used in cell culture experiments to
obtain quiescent cells, much higher basal levels were de-
tected than in proliferating cells (Fig. 5B, white bars com-
pared to black bars). Addition of simvastatin (30 lmol/L)
to these cells further activated caspase-3 to levels similar
to those obtained in proliferating cells.
To get an insight into the mechanism of simvastatin-
induced activation of caspase-3, proliferating mesangial
cells were concomitantly incubated with simvastatin plus
either geranylgeranylpyrophosphate (GGPP) or farne-
sylpyrophosphate (FPP). Both isoprenoids prevented the
activation of caspase-3 in a concentration-dependent
manner with GGPP apparently more effective than FPP
(Fig. 5C).
DNA fragmentation was determined by the dipheny-
lamine method to measure a late event in cellular apopto-
sis. In line with the caspase measurements, proliferating
mesangial cells showed no signs of strand breaks, whereas
growth-arrested cells were positive (Fig. 5D). Only the
highest concentrations of simvastatin (30 lmol/L) in-
duced a time-dependent increase in DNA strand breaks,
whereas cells treated with 10 lmol/L did not differ from
controls (data not shown).
Apoptosis was associated with necrosis as determined
by the release of the cytosolic protein adenylate kinase
into the cell culture supernatant. A significant increase
was observed when the cells were treated for 48 hours
with 30 lmol/L lovastatin or simvastatin (Fig. 5E). A sim-
ilar increase in caspase activity after 24 hours and cyto-
toxicity after 48 hours was also detectable when the cells
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Fig. 6. Toxic effects of simvastatin in human mesangial cells. (A) Hu-
man mesangial cells were incubated with increasing concentrations of
simvastatin. Caspase activity was determined after 24 hours () (N =
3) and 48 hours () (N = 4). To compare different experiments, the ac-
tivity in the absence of simvastatin was set to 1. ∗∗P < 0.01 compared to
cells treated with 0.3 lmol/L simvastatin. (B) Cleavage of procaspase-3
(32 kD) was detected by Western blot analysis after incubation of the
cells with simvastatin (0.3 to 30 lmol/L) for 48 hours. The blot is rep-
resentative of three experiments. (C) The homogenates analyzed for
caspase activity were also analyzed for p53 expression by Western blot
analysis. As a control for equal loading, b-actin was detected.
were incubated with high concentrations of the specific
inhibitor of the geranylgeranyltransferase L841 (Fig. 5F).
The different concentrations of simvastatin necessary
to affect gene expression and to induce apoptosis were
also obvious in a human mesangial cell line which has
been characterized previously with respect to inhibition
of connective tissue growth factor by simvastatin [18].
Activation of caspase-3 was not detectable after 24 hours,
but was induced after 48 hours at concentrations, which
have previously been shown to inhibit connective tissue
growth factor expression after 24 hours (Fig. 6A). Cleav-
age of procaspase-3 (32 kD) into active fragments (19 and
11 kD), another sign of apoptosis, was also observed after
48 hours (Fig. 6B). Induction of apoptosis was indepen-
dent of p53, as no change in the expression of this protein
was observed (Fig. 6C).
DISCUSSION
It is increasingly evident that statins exert direct cellu-
lar effects, which add to their therapeutic benefits. In-
cubation of mesangial cells with the lipophilic statins
simvastatin or lovastatin led to time- and concentration-
dependent alterations of the cytoskeletal architecture,
changes in gene expression as exemplified by the reduc-
tion of CTGF expression and reduced cell proliferation.
Higher concentrations were necessary to induce apopto-
sis and necrosis, which only occurred at concentrations
which severely impaired cell structure. We conclude that
by reducing the isoprenylation of signaling molecules of
the Rho family, statins alter distinct regulatory pathways
leading to functional alterations of mesangial cells.
In the present study mesangial cells were cultured in
serum containing medium and proliferation was assessed
without adding a specific external stimulus, because it is
assumed that in vivo under pathophysiologic conditions
mesangial cells are exposed to multiple signals which
are integrated to induce proliferation. The inhibitory ef-
fect of simvastatin and lovastatin on cell proliferation
was mimicked by the specific inhibitor of the geranyl-
geranyl transferase I, L841, showing the involvement of
geranylgeranyl-modified proteins, most likely proteins of
the Rho family. Geranylgeranylation has been shown
to be involved in cell cycle progression through G1/S
phase [26]. Inhibition of glucose-induced proliferation by
statins was also mediated by interference with the ger-
anylgeranylation of signaling molecules and shown to be
dependent on the differential gene expression of kinases
and their inhibitors [8].
Modulation of gene expression was examplified in our
study by the investigation of CTGF, a fibrogenic protein
associated with fibrotic kidney diseases in animal models
and in man [27, 28]. Concentrations of simvastatin, which
inhibited proliferation, also reduced CTGF expression,
which may add to their therapeutic effects observed in
several animal models. High glucose is one of the induc-
ers of connective tissue growth factor and it is assumed
that CTGF plays a functional role in diabetic nephropa-
thy [29]. Thus both, the inhibition of proliferation as well
as the interference with the expression of the fibrogenic
CTGF may explain beneficial effects of statins observed
in diabetes. As both effects are mediated primarily by in-
terference with geranylgeranylation one might speculate
that targeting the geranylgeranyl transferase might be a
means of interference with diabetic nephropathy. How-
ever, the extrapolation to the in vivo situation needs to be
cautioned, because the effect of statins on gene expres-
sion seems to be context-dependent. Interference with
RhoA signaling was sufficient to interfere with TGF-b–
induced CTGF in human fibroblasts [18, 30] and human
mesangial cells [21], but not in rat mesangial cells. These
differences require further investigation to understand
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the integration of different signaling pathways at the level
of CTGF gene expression.
Targeting of Rho proteins by simvastatin was evident
by changes in the actin cytoskeleton and the reduction
in modified RhoA. Although the synthesis of RhoA pro-
tein was up-regulated, this protein was not appropriately
modified to become activated as shown by the increased
amount of nongeranylgeranylated form of RhoA. In ac-
cordance with a reduced concentration of active RhoA,
the cell-spanning actin stress fibers were reduced, the for-
mation of which is mainly under the control of RhoA.
Very high concentrations of simvastatin, 30 lmol/L, led
to condensation of actin filaments around the nucleus and
a considerable change in cell structure and loss of cell at-
tachment indicative of impairment of all proteins of the
Rho family including Rac and Cdc42, which are responsi-
ble for the structure of filpodia and lamellipodia. Interest-
ingly enough, only about 10% of these cells showed signs
of DNA fragmentation as determined by the dipheny-
lamine assay determined after 24 hours. The nuclei of
most cells appeared contracted, but only few of the nu-
clei showed signs of apoptosis. As expected, prolonged
incubation with statins, which led to detachment of the
mesangial cells, was associated with increased numbers
of apoptotic cells and necrosis. Apoptosis following mor-
phologic changes has been described in proximal tubular
cells [31], supporting the differential effect of statins on
cellular functions: concentrations of simvastatin, which
strongly interfered with gene expression (10 lmol/L), did
not induce apoptosis within the same time frame. Dis-
sociation of antiproliferative and toxic effects was also
detected when the geranylgeranyl transferase was inhib-
ited. Induction of apoptosis and cell death thus seem to
be a sign of toxic effects of statins rather than to occur
simultaneously with the other cellular effects discussed
above.
Interference with geranylgeranyl modification of sig-
naling proteins by simvastatin leads to morphologic al-
terations of mesangial cells and modulation of gene ex-
pression, which seem to be closely related as they oc-
cur within the same concentration range and time frame,
whereas apoptotic cell death has to be considered a toxic
effect of statin treatment. More specific interference with
geranylgeranyl modification or direct targeting of RhoA
signaling pathways might be a means to mimic the thera-
peutically effective cellular effects of statins on glomeru-
lar mesangial cells.
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